feedback

Course Director

Robert Anders, MD, PhD
Robert Anders, MD, PhD

Johns Hopkins University
The Bloomberg~Kimmel Institute for Cancer Immunotherapy
Baltimore, Maryland

Faculty

Robert L. Ferris
Robert L. Ferris, MD, PhD

UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Lauren L. Ritterhouse
Lauren L. Ritterhouse, MD, MPH

The University of Chicago Medicine
Chicago, Illinois

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC
Credit Amount:1.5 Credits
Release Date:2018-Dec-27
Expiration Date:2019-Dec-26
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free

Activity Description and Educational Objectives

In this activity, pathology and oncology experts discuss the state of the evidence on cancer immunotherapies across the oncologic spectrum, and review the role and use of current and emerging biomarkers to guide clinical decisions in practice.

Upon completion of this activity, participants should be better able to:
  • Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations (eg, those targeting PD-1/PD-L1, CTLA-4, LAG-3, etc) across the spectrum of solid and liquid cancers
  • Describe evidence supporting the use of PD-L1, MSI/MMR, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies
  • Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances
  • Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes
  • Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations
  • Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer

Target Audience

This activity has been designed to meet the educational needs of pathologists and other healthcare professionals interested in precision immuno-oncology and immunotherapy biomarkers and/or those involved in cancer immunotherapy biomarker testing.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 27, 2018 - December 26, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC activity during the past 12 months.

Course Director and Moderator

Robert Anders, MD, PhD
Associate Professor of Pathology
Co-Director Tumor Microenvironment Lab
Johns Hopkins University
The Bloomberg~Kimmel Institute for Cancer Immunotherapy
Baltimore, Maryland

Robert Anders, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb; Five Prime Therapeutics, Inc.; FLX Bio, Inc.; National Institutes of Health (NIH); Roche Diagnostics; Stand up to Cancer; and The Fibrolamellar Cancer Foundation.
Consultant and/or Advisor for Adaptive Biotechnologies; AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics, Inc.; FLX Bio, Inc.; and Merck Sharp & Dohme.

Robert Anders, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.

Faculty

Robert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
Pittsburgh, Pennsylvania

Robert L. Ferris, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bain Capital, LP; Iovance Biotherapeutics, Inc.; and Ono Pharmaceutical Co. Ltd.
Grant/Research Support from Bristol-Myers Squibb; TESARO, Inc.; and VentiRx Pharmaceuticals.
Advisory Board for Amgen Inc.; AstraZeneca/MedImmune; Bristol-Myers Squibb; Eli Lilly and Company; EMD Serono, Inc.; Merck & Co., Inc.; Oncorus, Inc.; Pfizer Inc.; PPD (Benitec, Immunicum); Regeneron Pharmaceuticals, Inc.; and TESARO, Inc.
Other Financial or Material Support from AstraZeneca/MedImmune; Bristol-Myers Squibb; and Merck & Co., Inc. for clinical trial.

Robert L. Ferris, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.

Lauren L. Ritterhouse, MD, PhD
Section Director, Molecular Diagnostic Laboratory and Clinical Genomics Laboratory
Division of Genomic and Molecular Pathology
The University of Chicago Medicine
Chicago, Illinois

Lauren L. Ritterhouse, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb.

Lauren L. Ritterhouse, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations and/or cancer immunotherapy biomarker testing platforms.

CME/MOC Reviewers

Shaina Rozell, MD, MPH

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
The activity titled “The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies” has been registered to offer 1.5 Lifelong Learning (Part II) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit. Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Providership


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Foundation Medicine, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.